JP Stock MarketDetailed Quotes

4568 Daiichi Sankyo

Watchlist
  • 4310.0
  • -139.0-3.12%
20min DelayMarket Closed Dec 13 15:30 JST
8.39TMarket Cap41.20P/E (Static)

About Daiichi Sankyo Company

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Company Profile

Symbol4568
Company NameDaiichi Sankyo
Founded2005-09-28
MarketTSE Prime
Employees18907
Fiscal Year Ends03-31
Address3-5-1, Nihonbashi-honcho Chuo-ku
Zip Code103-8426
Phone03-6225-1111

Company Executives

  • Name
  • Position
  • Salary
  • Sunao Manabe
  • Executive Chairman of the Board and Chief Executive Officer
  • --
  • Takashi Matsumoto
  • Director, Managing Executive Officer, Chief Human Resources Officer and Head of Global HR
  • --
  • Hiroyuki Okuzawa
  • Director, President and Chief Operating Officer
  • --
  • Takashi Fukuoka
  • Director, Senior Executive Officer and Head, Global Corporate Strategy
  • --
  • Shoji Hirashima
  • Director, Senior Executive Officer and Head, Japan Business Unit
  • --
  • Kazuaki Kama
  • Chairman of the Board
  • --
  • Yasuhiro Komatsu
  • Independent Director
  • --
  • Yo Honma
  • Independent Director
  • --
  • Takaaki Nishii
  • Independent Director
  • --
  • Sawako Nohara
  • Independent Director
  • --

Business Data

Revenue by product

No Data

Heat List
JP
Overall
Symbol
Price
% Chg

No Data